CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 167 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $149,484,045 | -14.1% | 5,431,833 | +5.9% | 0.03% | -9.1% |
| Q2 2023 | $174,109,318 | +15.7% | 5,131,427 | +22.7% | 0.03% | +10.0% |
| Q1 2023 | $150,454,364 | -27.4% | 4,181,611 | -10.0% | 0.03% | -28.6% |
| Q4 2022 | $207,157,438 | +139.2% | 4,647,912 | +50.9% | 0.04% | +133.3% |
| Q3 2022 | $86,600,000 | +13.1% | 3,080,733 | +8.5% | 0.02% | +20.0% |
| Q2 2022 | $76,577,000 | -36.3% | 2,840,383 | -19.5% | 0.02% | -28.6% |
| Q1 2022 | $120,227,000 | +42.3% | 3,529,840 | +61.5% | 0.02% | +50.0% |
| Q4 2021 | $84,468,000 | -28.2% | 2,185,976 | +0.3% | 0.01% | -30.0% |
| Q3 2021 | $117,717,000 | +79.3% | 2,180,352 | +11.1% | 0.02% | +81.8% |
| Q2 2021 | $65,642,000 | +68.7% | 1,962,999 | +3.9% | 0.01% | +57.1% |
| Q1 2021 | $38,907,000 | +2258.0% | 1,888,736 | +1905.0% | 0.01% | – |
| Q4 2020 | $1,650,000 | – | 94,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,017,524 | $20,961,000 | 7.56% |
| Octagon Capital Advisors LP | 561,398 | $11,565,000 | 4.36% |
| COMMODORE CAPITAL LP | 369,951 | $7,621,000 | 3.04% |
| Opaleye Management Inc. | 985,000 | $20,291,000 | 2.98% |
| VR Adviser, LLC | 1,240,610 | $25,557,000 | 2.77% |
| TSP Capital Management Group, LLC | 359,229 | $7,400,000 | 2.61% |
| RTW INVESTMENTS, LP | 3,908,947 | $80,524,000 | 1.26% |
| Ghost Tree Capital, LLC | 250,000 | $5,150,000 | 1.21% |
| Tri Locum Partners LP | 196,672 | $4,051,000 | 1.00% |
| Redmile Group, LLC | 3,387,788 | $69,788,000 | 0.98% |